2026-03-24, Tue.

Top Stories       Business       Culture & Life       Science & Technology       World

Lecture

Notification

 

NEWS > Business


First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra¡¯s Regenerative Properties

Date: 2026-03-15

ZUG, SWITZERLAND -- Galderma (SIX: GALD), the pure-play dermatology category leader, unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Sculptra® across nine diverse patients - who were all new to injectable aesthetics - over two years.[1] This innovative initiative will offer a rare and authentic real-life perspective on the power of regenerative biostimulation to deliver personalized outcomes, and demonstrate how Sculptra adapts to different skin types, life stages, and aesthetic goals.[1]

Sculptra is the first proven regenerative biostimulator, backed by over 25 years of clinical use.[2-6] With a unique poly-L-lactic acid (PLLA-SCA™) formulation, Sculptra re-engages the skin’s renewal process, stimulating collagen and elastin for healthy looking skin.[3,7-11] Over the decades, it has evolved into a versatile treatment that delivers regenerative benefits across all three skin layers, helping to gradually restore volume, firmness, radiance and skin quality, and smoothing wrinkles and folds over time.[2,3,7-14]

“What excites me about this unique program is how it aims to capture the nuance of clinical practice: different protocols, different goals, and different outcomes, all unified by a science-first approach to aesthetic personalization. And beyond the science, we also notice an emotional journey - seeing patients regain confidence, feel more like themselves, and experience a deeper sense of wellbeing as their natural beauty is restored over time.”

MS. PRIYANKA CHADHA, FRCS (PLAST)
CONSULTANT PLASTIC SURGEON, GLOBAL EDUCATOR
AMER CLINIC, LONDON

Through self-recorded video diaries and clinical check-ins, We Are All Sculptra will follow nine patients - who were all new to injectable aesthetics - over two years, offering a long-term view of how Sculptra performs over time.[1] Its launch captures the patients’ personal reflections, results, and before & after treatment imagery, offering a powerful lens into both clinical outcomes and emotional impact.[1]

The campaign highlights the rich diversity of real patients, spanning age, gender identity, ethnicity, and skin biology.[1] Grounded in Galderma’s AART™ (Assessment, Anatomy, Range, and Treatment) methodologies and HIT™ (Holistic Individualised Treatment) protocols, it demonstrates the extent to which regenerative aesthetics can be tailored to individual goals and skin needs, by combining structured clinical assessment with holistic, individualized treatment planning.[1]

Whether renewing natural volume, improving skin quality, or repositioning tissue for a lifted appearance, each case will highlight Sculptra’s adaptability across diverse indications and patient needs.[1] As well its natural, long-lasting clinical outcomes, the campaign captures the emotional resonance of treatment, with improved confidence, self-recognition, and wellbeing seen throughout the group, while also leaving them with a positive first impression of aesthetic treatments.[1]

“With We Are All Sculptra, we’ll redefine what regenerative biostimulation looks like in real life. This program is a bold expression of Galderma’s commitment to science-led personalization, showcasing how Sculptra performs across diverse skin types, treatment approaches, and patient goals. It’s not just about representation; it’s about proving that versatility and inclusivity are inseparable in modern aesthetic medicine.”

ALAN D. WIDGEROW, MBBCH, MMED, FCS, FACS
CHIEF SCIENTIFIC OFFICER GALDERMA, HEAD SKIN SCIENCE CENTER FOR INNOVATION

References

[1] Galderma. Data on file. We Are All Sculptra. 2025
[2] U.S. Food and Drug Administration. Sculptra summary of safety and effectiveness data. Available online. Accessed December 2025.
[3] Zhang Y, et al. In vivo inducing collagen regeneration of biodegradable polymer microspheres. Regen Biomater. 2021;8(5):rbab042. doi: 10.1093/rb/rbab042.
[4] Waibel J, et al. A randomized, comparative study describing the gene signatures of poly-L-lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress; February 3-6. 2024; Paris, France.
[5] Huth S, et al. Molecular insights into the effects of PLLA-SCA on gene expression and collagen synthesis in human 3d skin models containing macrophages. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.7791.
[6] Zubair R, et al. SPLASH: Split-body randomized clinical trial of poly-L-lactic acid for adipogenesis and volumization of the hip dell. Dermatol Surg. 2024;50(12):1155-1162. doi: 10.1097/DSS.0000000000004417.
[7] Widgerow A, et al. A randomized, comparative study describing the gene signatures of Poly-L-Lactic Acid (PLLA-SCA) and Calcium Hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress, February 1-3, 2024, Paris, France.
[8] Waibel J, et al. Gene Analysis of Biostimulators: PLLA-SCA Triggers Regenerative Morphogenesis while CaHA-R Induces Inflammation upon Facial Injection. Poster presented at ASDS 2024, October 17-20, 2024, Orlando, Florida, United States.
[9] Waibel J, et al. Bulk RNA-seq Analysis of Poly-L-Lactic Acid (PLLA-SCA) vs Calcium Hydroxyapetite (CaHA-R) Reveals a Novel, Adipocyte Mediated Regenerative Mechanism of Action Unique to PLLA. Poster presented at ASDS 2024 Annual Meeting, October 17-20, 2024, Orlando, Florida, United States.
[10] Haddad S, et al. Evaluation of the biostimulatory effects and the level of neocollagenesis of dermal fillers: a review. Int J Dermatol. 2022;61:1284-1288. doi: 10.1111/ijd.16229.
[11] Vleggaar D, et al. Consensus recommendations on the use of injectable poly-L-lactic-acid for facial and nonfacial volumization. J Drugs Dermatol. 2014;13(4 Suppl):s44-s51.
[12] Narins RS, et al. A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol. 2010;62(3):448-62. doi: 10.1016/j.jaad.2009.07.040.
[13] Galderma. Data on File (MA-47133).
[14] Mu X, et al. 12-Month Effectiveness and Safety of PLLA Treatment of Midface in Chinese Subjects: A Multicenter, Randomized, No-Treatment Controlled Study. Presented at AMWC. March 30 to April 1, 2023. Monte-Carlo, Monaco.
[15] Zhang S and Duan E. Fighting against skin aging: the way from bench to bedside. Cell Transpl. 2018;27(5):729-738. doi: 10.1177/0963689717725755.
[16] Shuster S, Black MM, and McVitie E. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93(6):639-643. doi: 10.1111/j.1365-2133.1975.tb05113.x.
[17] Goldberg D, et al. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39:915-922. doi: 10.1111/dsu.12164.
[18] Zarbafian M, et al. The emerging field of regenerative aesthetics—where we are now. Dermatol Surg. 2022;48:101-108. doi: 10.1097/DSS.0000000000003239.
[19] Hexsel D, Hexsel CL, and Cotofana S. Introducing the L-Lift: A Novel Approach To Treat Age-Related Facial Skin Ptosis Using A Collagen Stimulator. Dermatol Surg. 2020;46(8):1122-1124. doi: 10.1097/DSS.0000000000002015.
[20] Fabi S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at AMWC. March 30 - April 1, 2023. Monte-Carlo, Monaco.



 to the Top List of News

Newmont Reports 2025 Mineral Reserves of 118.2 Million Gold Ounces and 12.5 Million Tonnes of Copper
KleanNara Partners with Rimini Street to Accelerate Digital Transformation
INNIO signs Definitive Agreement to Acquire Enerflex APAC Operations, Expanding Service Capabilities in the Asia-Pacific Region
Andersen Consulting Broadens Data and Analytics Capabilities with Insight Consulting
1089 Inc., Price Forbes & Oka-Lloyd¡¯s Syndicate 1922 Launch Carbon Asset Insurance for Transport & Energy
Kao¡¯s Bioré Expands Global Reach with South Korea Entry and Unified Campaign
Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting

 

SS&C Seamlessly Transitions REI Super¡¯s Member Administration
DCO Launches Global ¡°Ctrl+Alt+Delete¡± Campaign to Combat Online Misi...
ExaGrid Achieves Customer Milestone
EUGF 2026, Reaffirming the Value of European Sustainable Agriculture i...
Laserfiche Announces 2026 Run Smarter¢ç Award Winners
Andersen Consulting Expands Executive Talent Capabilities With Lansdow...
Cubic Corporation Optimizes SAP Support with Rimini Street to Accelera...

 

 

60, Gamasanro 27gil, Guro-gu, Seoul, Korea, e-mail: news@newsji.com

Copyright, NEWSJI NETWORK.

.